United Therapeutics (UTHR) Set to Announce Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is scheduled to be releasing its earnings data before the market opens on Wednesday, May 1st. Analysts expect United Therapeutics to post earnings of $5.63 per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The company had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. United Therapeutics’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.67 earnings per share. On average, analysts expect United Therapeutics to post $23 EPS for the current fiscal year and $25 EPS for the next fiscal year.

United Therapeutics Stock Down 0.9 %

UTHR opened at $233.85 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. United Therapeutics has a one year low of $204.44 and a one year high of $261.54. The business’s fifty day moving average is $233.74 and its two-hundred day moving average is $228.76. The company has a market cap of $11.00 billion, a price-to-earnings ratio of 11.79 and a beta of 0.52.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent research reports. Wedbush restated an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. Wells Fargo & Company upped their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. HC Wainwright restated a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and upped their price objective for the company from $213.00 to $215.00 in a research report on Monday, February 12th. Finally, Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $294.25.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 15,000 shares of the company’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $248.33, for a total value of $3,724,950.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $32,282.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the company’s stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $248.33, for a total transaction of $3,724,950.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $32,282.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $215.01, for a total value of $1,290,060.00. Following the sale, the executive vice president now owns 36,599 shares of the company’s stock, valued at $7,869,150.99. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 136,990 shares of company stock worth $32,239,641. 12.50% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.